Even though you are a separate company to us, I really feel you are part of the family."
We work in true partnership with each client, taking the time to gain appreciation for each business.
The Halsin team of directors combine over 20 years experience in media relations, investor relations and small business counseling through positions held with leading specialty PR/IR firms. Our track record illustrates how effective we are in communicating a company’s story to all influential audiences.
We develop insightful media and investor relations programs tailored specifically to each client’s needs. Our interactive management approach is results-oriented, combining astute and informed counsel with superior program execution.
Integrity is a cornerstone of our practice. We work with only a few clients at any given time, ensuring our commitment of the resources needed to provide superior service.
Mike Sinclair is a co-founder of Halsin Partners with over 10 years experience in strategic communications within the pharmaceutical and biotechnology industries. At Halsin, Mike is primarily responsible for directing the media relations and corporate communications programs for clients.
Previously, Mike was Director, European Life Science Practice at Burns McClellan, a transatlantic PR and IR agency focused on the healthcare and biotech industry, based in London. Before this, Mike was a Vice President in the San Francisco office of Burns McClellan. Prior to his tenure at Burns McClellan, Mike was Senior Editor of R&D focus. In this capacity, he was responsible for the writing and editing of the weekly publication, Drug News, as well as managing a team of writers. He has also authored several papers on a wide range of therapeutic areas. Moreover, Mike has chaired and participated on panels at several industry conferences.
Heike Heinrichs is a co-founder of Halsin Partners with more than 10 years experience in investor relations and corporate communications for the biotech industry. Heike is responsible for directing the investor relations and strategic communications activities on behalf of the firm’s clients. Moreover, she has throughout her career developed a particular expertise in training management teams to lay the appropriate groundwork for effective investor, analyst and financial media interaction.
Previously, Heike worked with Burns McClellan in London and Munich, where she spearheaded the investor relations franchise as Group Supervisor, Investor Relations for Europe. Prior to joining Burns McClellan, Heike was a Senior Manager with the European subsidiary of Noonan Russo. In this capacity she oversaw the investor relations, media relations and corporate communications programs of more than half of the agency’s continental clients. Throughout her tenure, Heike has counseled a number Europe’s first publicly traded biotech companies, including QIAGEN, Morphosys, Cerep and Pharming, through their Initial Public Offerings, Secondary Offerings and M&A.